On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > ACADEMIA
ACADEMIA
- Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
August 6, 2013
- The Lancet Has Not Received Notification from Jikei University on Investigation Findings: Spokesperson
August 1, 2013
- Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
July 31, 2013
- Role of Companies in Clinical Research Discussed at JAPhMed Annual Meeting
July 24, 2013
- University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
- Univ. Fails to Question Ex-Novartis Employee over KYOTO Study, Says Internal Probe “Has Limitations”
July 16, 2013
- “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
- Arzerra, Japan’s 1st Antibody for CLL, Will Expand Treatment Options: Dr Ogawa of Tokai Univ.
July 11, 2013
- Nearly 30% of RA Patients Show LDA 3 Years After Discontinuing Remicade: Prof. Tanaka of Univ. of Occupational and Environmental Health
July 11, 2013
- Orencia Particularly Suitable for Elderly RA Patients: Prof. Takeuchi of Keio University
July 8, 2013
- “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
- NHO Attains 30% Volume-Based Generic Target in FY2012
June 28, 2013
- JSOG Sets Up Investigative Panel on HPV Vaccines to Examine Safety
June 26, 2013
- Dapagliflozin Significantly Reduces Plasma Glucose in PIII Study in Japan, Findings Reported at ADA
June 25, 2013
- SCJ Statement Calls for Close Consultation with Experts in Planning Japanese Version of NIH
June 25, 2013
- Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says
June 25, 2013
- More Treatment Options for FD Patients with Acofide Launch: Prof. Kinoshita of Shimane University
June 11, 2013
- Clinical Pharmacology Network to Go Into Operation with 8 Institutions
June 6, 2013
- Japan College of Rheumatology Issues Guidelines on Xeljanz Use
June 6, 2013
- Cetuximab Add-on Therapy Fails to Improve PFS in Operable Colorectal Liver Metastasis Patients: ASCO
June 4, 2013
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…